References
- Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13 (2): 314–322.
- Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14 (1): 58–65.
- Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14 (2): 422–428.
- Ravdin PM, Burris HA, 3rd, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracene-dione-resistant breast cancer. J Clin Oncol 1995; 13 (12): 2879–2885.
- Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13 (12): 2886–2894.
- Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 2001; 6(Suppl 3): 26–29.
- Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treat-ment of metastatic breast cancer. J Clin Oncol 1998; 16 (10): 3353–3361.
- Hainsworth JD, Burris HA, 3rd, Greco FA. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol 1999; 26 (3 Suppl 10): 19-24.
- Hainsworth JD, Burris HA, 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16 (6): 2164–2168.
- Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994; 12 (7): 1458-1467.
- Hainsworth JD, Burris HA, 3rd, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19 (15): 3500–3505.
- Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18 (6): 1212–1219.
- Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxotereo) in patients with metastatic breast can-cer. Ann Oncol 2001; 12 (10): 1393–1398.
- Aihara T, Kim Y, Takatsuka Y. Phase II study of week-ly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002; 13 (2): 286–292.
- Climent MA, Ruiz A, Llombart-Cussac A. Weekly doc-etaxel in patients with advanced malignancies. Toxicity profile and activity results. Proc Am Soc Clin Oncol 1999; 18: 453a.
- Loeffler TM, Freund W, Hausamen TU. Activity of weekly Taxotere (TXT) in patients with metastatic breast can-cer. Proc Am Soc Clin Oncol 1998; 17: 113a.
- Ramos M, Gonzalez-Ageitos A, Vicente J. Weekly doc-etaxel (D) for metastatic breast cancer (MBC) progressing after anthracyclines treatment. Proc Am Soc Clin Oncol 2000; 19: 445a.
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47 (1): 207–214.
- Guidelines for the reporting of adverse drug reactions. Bethesda: Division of Cancer Treatment, National Cancer Institute; 1988.
- Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000; 59 (3): 621–651.
- O'Brien ME, Leonard RC, Barrett-Lee PJ, Eggleton SP, Bizzari JP. Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol 1999; 10 (2): 205–210.
- Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13 (10): 2643-2655.
- Kim Y, Takatsuka Y, Tanigawara Y, et al. Weekly doc-etaxel for patients with recurrent breast cancer: clinical results and pharmacokinetic/pharmacodynamic assessment. Proc Am Soc Clin Oncol 2000; 19: 436a.
- Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly docetaxel: a potentially pre-ventable side effect. Ann Oncol 2002; 13 (2): 218–221.
- Jackisch C, Eibach HW, Kunth A, et al. Phase-II trial of docetaxel weekly as dose sense treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 19: 417a.